APDA-Funded Research Discovers New Role of Alpha Synuclein

In an exciting new study, researchers at Brigham and Women’s Hospital in Boston, MA, led by APDA Cotzias Fellowship*...see more awardee Dr. Vikram Khurana, demonstrated a new role for the protein involved in Parkinson’s disease (PD) pathology, alpha-synuclein. In addition to alpha-synuclein interacting with vesicles, or small transport structures within the cell, this new study shows […]

Read More

New Clinical Use for Gocovri

Adamas announced that the Food and Drug Administration (FDA) approved Gocovri for a second indication – as an add-on...see more treatment to carbidopa/levodopa in Parkinson’s disease (PD) patients who are experiencing OFF episodes. Previously, Gocovri was only approved for treatment of Levodopa-induced dyskinesias. You can learn more about managing dyskinesias and OFF episodes in this webinar. […]

Read More

New technology from Abbott allows for remote programming of DBS device

Abbott, one of the manufacturers of deep brain stimulation (DBS) devices for Parkinson’s disease (PD) recently released NeuroSphereTM Virtual...see more Clinic, a technology that allows for virtual visits between patients and their DBS neurologist and is the first system to allow for remote programming of the DBS device. Currently, a device can be programmed so that […]

Read More

APDA CENTER AT BRIGHAM AND WOMEN’S HOSPITAL REPORTS EXCITING CORRELATION BETWEEN GLUCOCEREBROSIDASE ACTIVITY AND PARKINSON’S DISEASE

In an exciting new study, researchers at the APDA-funded Center studied the relationship between the activity of the glucocerebrosidase...see more (GBA) enzyme and the risk of Parkinson’s disease (PD). This insight may help shed light on possible future treatments. The glucocerebrosidase (GBA) enzyme, encoded by the GBA gene, is a protein used by the body to […]

Read More

New Deep Brain Stimulation (DBS) Technology Now Available

Medtronic announces introduction of Percept PC Neurostimulator with Brainsense Technology On June 26, 2020 Medtronic announced the introduction of...see more an upgraded deep brain stimulation (DBS) system known as PerceptTM PC Neurostimulator with BrainsenseTM Technology. The technology in the new system is the first to not only deliver electrical stimulation to the brain, with the goal […]

Read More

A statement from APDA in this time of unrest

All of us at the American Parkinson Disease Association (APDA) support equality for all and reject racism.  Our programs...see more are open to everyone and we foster a safe and welcoming place for all to join us, whether virtually or in person.  Disparities and injustice exist on many levels, including within the healthcare system. At APDA, […]

Read More

New medication approved by FDA for OFF symptoms

Kynmobi Sunovion Pharmaceuticals announced that the Food and Drug Administration (FDA) approved Kynmobi® (apomorphine hydrochloride), a new sublingual medication...see more for fast relief of OFF symptoms of Parkinson’s disease (PD). Apomorphine acts as a dopamine agonist, mimicking the effects of dopamine in the brain. It was previously only available as Apokyn, an injectable medication that provides […]

Read More

New drug approved for OFF episodes

Today, Neurocrine Biosciences announced that the Food and Drug Administration (FDA) approved ONGENTYS ® (opicapone), a new medication for...see more treatment of Parkinson’s disease (PD). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor to be used once-daily as an add-on treatment to levodopa for patients who are experiencing OFF time with their current medication regimen. Opicapone is in […]

Read More